InflaRx (IFRX) Competitors $1.34 -0.03 (-2.19%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.35 +0.01 (+0.75%) As of 08:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IFRX vs. ALT, DRUG, FDMT, AMRN, IMAB, SCPH, ALEC, RAPT, GALT, and ALDXShould you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Altimmune (ALT), Bright Minds Biosciences (DRUG), 4D Molecular Therapeutics (FDMT), Amarin (AMRN), I-Mab (IMAB), scPharmaceuticals (SCPH), Alector (ALEC), Rapt Therapeutics (RAPT), Galectin Therapeutics (GALT), and Aldeyra Therapeutics (ALDX). These companies are all part of the "pharmaceutical products" industry. InflaRx vs. Its Competitors Altimmune Bright Minds Biosciences 4D Molecular Therapeutics Amarin I-Mab scPharmaceuticals Alector Rapt Therapeutics Galectin Therapeutics Aldeyra Therapeutics InflaRx (NASDAQ:IFRX) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment. Is IFRX or ALT more profitable? InflaRx has a net margin of 0.00% compared to Altimmune's net margin of -438,730.03%. Altimmune's return on equity of -62.63% beat InflaRx's return on equity.Company Net Margins Return on Equity Return on Assets InflaRxN/A -71.76% -57.68% Altimmune -438,730.03%-62.63%-55.29% Do insiders & institutionals have more ownership in IFRX or ALT? 42.4% of InflaRx shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 4.4% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate IFRX or ALT? InflaRx currently has a consensus price target of $6.20, suggesting a potential upside of 362.69%. Altimmune has a consensus price target of $17.40, suggesting a potential upside of 360.32%. Given InflaRx's stronger consensus rating and higher probable upside, research analysts clearly believe InflaRx is more favorable than Altimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Altimmune 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Does the media refer more to IFRX or ALT? In the previous week, Altimmune had 20 more articles in the media than InflaRx. MarketBeat recorded 21 mentions for Altimmune and 1 mentions for InflaRx. InflaRx's average media sentiment score of 1.93 beat Altimmune's score of 0.29 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Altimmune 2 Very Positive mention(s) 0 Positive mention(s) 18 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, IFRX or ALT? InflaRx has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Which has stronger valuation and earnings, IFRX or ALT? InflaRx has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInflaRx$162.83K552.48-$49.85M-$0.80-1.68Altimmune$20K16,680.57-$95.06M-$1.18-3.20 SummaryInflaRx beats Altimmune on 10 of the 15 factors compared between the two stocks. Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IFRX vs. The Competition Export to ExcelMetricInflaRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.96M$3.15B$5.80B$10.44BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-1.6721.0580.5126.85Price / Sales552.48397.51520.52163.30Price / CashN/A44.8326.0131.15Price / Book1.199.6215.746.42Net Income-$49.85M-$53.02M$3.30B$271.73M7 Day Performance8.94%1.43%3.93%2.82%1 Month Performance46.69%3.42%5.30%6.60%1 Year Performance-13.55%11.20%80.46%28.60% InflaRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IFRXInflaRx3.234 of 5 stars$1.34-2.2%$6.20+362.7%-13.5%$89.96M$162.83K-1.6760Positive NewsALTAltimmune2.5658 of 5 stars$3.87+8.4%$17.40+349.6%-51.5%$315.08M$20K-3.2850Trending NewsHigh Trading VolumeDRUGBright Minds Biosciences3.0966 of 5 stars$50.15+12.2%$81.00+61.5%+4,179.5%$314.73MN/A-53.92N/AAnalyst UpgradeHigh Trading VolumeFDMT4D Molecular Therapeutics2.6609 of 5 stars$7.10+6.6%$30.40+328.2%-44.5%$311.04M$40K-2.01120Positive NewsAMRNAmarin0.5332 of 5 stars$14.92+2.2%$12.00-19.6%+30.1%$301.97M$228.61M-4.07360IMABI-Mab2.4061 of 5 stars$3.65-1.1%$7.00+91.8%+250.9%$301.33MN/A0.00380Analyst DowngradeSCPHscPharmaceuticals4.287 of 5 stars$5.62-0.2%$7.78+38.5%+8.7%$300.07M$36.33M-3.1030ALECAlector3.6814 of 5 stars$3.13+6.1%$4.17+33.1%-47.3%$298.58M$100.56M-2.70270Positive NewsRAPTRapt Therapeutics3.6664 of 5 stars$20.50+13.9%$21.57+5.2%+38.7%$297.68MN/A-1.4580Positive NewsHigh Trading VolumeGALTGalectin Therapeutics1.7207 of 5 stars$4.64+1.1%$6.00+29.3%+73.3%$294.04MN/A-7.259Positive NewsALDXAldeyra Therapeutics1.3332 of 5 stars$5.01+2.2%$9.50+89.6%-16.3%$293.49MN/A-5.8910 Related Companies and Tools Related Companies Altimmune Competitors Bright Minds Biosciences Competitors 4D Molecular Therapeutics Competitors Amarin Competitors I-Mab Competitors scPharmaceuticals Competitors Alector Competitors Rapt Therapeutics Competitors Galectin Therapeutics Competitors Aldeyra Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IFRX) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThis Crypto Could Thrive as Global Tensions Rise Right as capital begins to rotate back into crypto, my top...Crypto 101 Media | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IFRX Stock Alerts